Publications

Found 2 results
Filters: Author is C.M. Willis  [Clear All Filters]
2011
R. D. Prinz, Willis, C. M., Viloria-Petit, A., and Klüppel, M., Elimination of breast tumor-associated chondroitin sulfate promotes metastasis, vol. 10, pp. 3901-3913, 2011.
Alini M and Losa GA (1991). Partial characterization of proteoglycans isolated from neoplastic and nonneoplastic human breast tissues. Cancer Res. 51: 1443-1447. PMid:1997183   Basappa MS, Sugahara KN, Lee CM, ten Dam GB, et al. (2009). Involvement of chondroitin sulfate E in the liver tumor focal formation of murine osteosarcoma cells. Glycobiology 19: 735-742. http://dx.doi.org/10.1093/glycob/cwp041 PMid:19293233   Bradbury EJ and Carter LM (2011). Manipulating the glial scar: chondroitinase ABC as a therapy for spinal cord injury. Brain Res. Bull. 84: 306-316. http://dx.doi.org/10.1016/j.brainresbull.2010.06.015 PMid:20620201   Cafferty WBJ, Yang SH, Duffy PJ, Li S, et al. (2007). Functional axonal regeneration through astrocytic scar genetically modified to digest chondroitin sulfate proteoglycans. J. Neurosci. 27: 2176-2185. http://dx.doi.org/10.1523/JNEUROSCI.5176-06.2007 PMid:17329414 PMCid:2848955   Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, et al. (2011). Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res. 13: R58. http://dx.doi.org/10.1186/bcr2895 PMid:21658254 PMCid:3218947   Coulson-Thomas YM, Coulson-Thomas VJ, Filippo TR, Mortara RA, et al. (2008). Adult bone marrow-derived mononuclear cells expressing chondroitinase AC transplanted into CNS injury sites promote local brain chondroitin sulphate degradation. J. Neurosci. Methods 171: 19-29. http://dx.doi.org/10.1016/j.jneumeth.2008.01.030 PMid:18417222   Habuchi O (2000). Diversity and functions of glycosaminoglycan sulfotransferases. Biochim. Biophys. Acta 1474: 115-127. http://dx.doi.org/10.1016/S0304-4165(00)00016-7   Heinegard D (2009). Proteoglycans and more - from molecules to biology. Int. J. Exp. Pathol. 90: 575-586. http://dx.doi.org/10.1111/j.1365-2613.2009.00695.x PMid:19958398 PMCid:2803248   Hendrix MJ, Seftor EA, Kirschmann DA, Quaranta V, et al. (2003). Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N. Y. Acad. Sci. 995: 151-161. http://dx.doi.org/10.1111/j.1749-6632.2003.tb03218.x PMid:12814947   Hendrix MJ, Seftor EA, Seftor REB, Kasemeier-Kulesa J, et al. (2007). Reprogramming metastatic tumour cells with embryonic microenvironments. Nat. Rev. Cancer 7: 246-255. http://dx.doi.org/10.1038/nrc2108 PMid:17384580   Hochberg MC (2010). Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage 18 (Suppl 1): S28-S31. http://dx.doi.org/10.1016/j.joca.2010.02.016 PMid:20399895   Hogan BV, Peter MB, Shenoy H, Horgan K, et al. (2010). Intramammary lymph node metastasis predicts poorer survival in breast cancer patients. Surg. Oncol. 19: 11-16. http://dx.doi.org/10.1016/j.suronc.2008.12.009 PMid:19171479   Iida J, Wilhelmson KL, Ng J, Lee P, et al. (2007). Cell surface chondroitin sulfate glycosaminoglycan in melanoma: role in the activation of pro-MMP-2 (pro-gelatinase A). Biochem. J. 403: 553-563. http://dx.doi.org/10.1042/BJ20061176 PMid:17217338 PMCid:1876388   Kalathas D, Theocharis DA, Bounias D, Kyriakopoulou D, et al. (2009). Alterations of glycosaminoglycan disaccharide content and composition in colorectal cancer: structural and expressional studies. Oncol. Rep. 22: 369-375. PMid:19578779   Kawashima H, Hirose M, Hirose J, Nagakubo D, et al. (2000). Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J. Biol. Chem. 275: 35448-35456. http://dx.doi.org/10.1074/jbc.M003387200 PMid:10950950   Kawashima H, Atarashi K, Hirose M, Hirose J, et al. (2002). Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1-3GalNAc(4,6-O-disulfate) interact with L- and P-selectin and chemokines. J. Biol. Chem. 277: 12921-12930. http://dx.doi.org/10.1074/jbc.M200396200 PMid:11821431   Kenny PA, Lee GY and Bissell MJ (2007). Targeting the tumor microenvironment. Front Biosci. 12: 3468-3474. http://dx.doi.org/10.2741/2327 PMid:17485314 PMCid:2841020   Kim IS and Baek SH (2010). Mouse models for breast cancer metastasis. Biochem. Biophys. Res. Commun. 394: 443-447. http://dx.doi.org/10.1016/j.bbrc.2010.03.070 PMid:20230796   Klüppel M (2010). The roles of chondroitin-4-sulfotransferase-1 in development and disease. Prog. Mol. Biol. Transl. Sci. 93: 113-132. http://dx.doi.org/10.1016/S1877-1173(10)93006-8   Klüppel M (2011). Efficient secretion of biologically active Chondroitinase ABC from mammalian cells in the absence of an N-terminal signal peptide. Mol. Cell Biochem. 351: 1-11. http://dx.doi.org/10.1007/s11010-010-0705-1 PMid:21213020   Klüppel M, Vallis KA and Wrana JL (2002). A high-throughput induction gene trap approach defines C4ST as a target of BMP signaling. Mech. Dev. 118: 77-89. http://dx.doi.org/10.1016/S0925-4773(02)00198-3   Klüppel M, Wight TN, Chan C, Hinek A, et al. (2005). Maintenance of chondroitin sulfation balance by chondroitin- 4-sulfotransferase 1 is required for chondrocyte development and growth factor signaling during cartilage morphogenesis. Development 132: 3989-4003. http://dx.doi.org/10.1242/dev.01948 PMid:16079159   Kovalszky I, Pogany G, Molnar G, Jeney A, et al. (1990). Altered glycosaminoglycan composition in reactive and neoplastic human liver. Biochem. Biophys. Res. Commun. 167: 883-890. http://dx.doi.org/10.1016/0006-291X(90)90606-N   Krasnokutsky S, Samuels J and Abramson SB (2007). Osteoarthritis in 2007. Bull. NYU Hosp. Jt. Dis. 65: 222-228. PMid:17922674   Kusche-Gullberg M and Kjellen L (2003). Sulfotransferases in glycosaminoglycan biosynthesis. Curr. Opin. Struct. Biol. 13: 605-611. http://dx.doi.org/10.1016/j.sbi.2003.08.002 PMid:14568616   LaBarge MA, Petersen OW and Bissell MJ (2007). Of microenvironments and mammary stem cells. Stem. Cell Rev. 3: 137-146. http://dx.doi.org/10.1007/s12015-007-0024-4 PMid:17873346 PMCid:3004778   Li F, Ten Dam GB, Murugan S, Yamada S, et al. (2008). Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells. J. Biol. Chem. 283: 34294-34304. http://dx.doi.org/10.1074/jbc.M806015200 PMid:18930920 PMCid:2662238   Luo J, Kato M, Wang H, Bernfield M, et al. (2001). Heparan sulfate and chondroitin sulfate proteoglycans inhibit E-selectin binding to endothelial cells. J. Cell Biochem. 80: 522-531. http://dx.doi.org/10.1002/1097-4644(20010315)80:4<522::AID-JCB1006>3.0.CO;2-H   Mego M, Mani SA and Cristofanilli M (2010). Molecular mechanisms of metastasis in breast cancer - clinical applications. Nat. Rev. Clin. Oncol. 7: 693-701. http://dx.doi.org/10.1038/nrclinonc.2010.171 PMid:20956980   Monzavi-Karbassi B, Stanley JS, Hennings L, Jousheghany F, et al. (2007). Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines. Int. J. Cancer 120: 1179-1191. http://dx.doi.org/10.1002/ijc.22424 PMid:17154173   Mueller MM and Fusenig NE (2004). Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4: 839-849. http://dx.doi.org/10.1038/nrc1477 PMid:15516957   Olsen EB, Trier K, Eldov K and Ammitzboll T (1988). Glycosaminoglycans in human breast cancer. Acta Obstet. Gynecol. Scand. 67: 539-542. http://dx.doi.org/10.3109/00016348809029866 PMid:3239385   Pothacharoen P, Siriaunkgul S, Ong-Chai S, Supabandhu J, et al. (2006). Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. J. Biochem. 140: 517-524. http://dx.doi.org/10.1093/jb/mvj181 PMid:16936295   Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, et al. (1997). Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin. Cancer Res. 3: 983-992. PMid:9815775   Ricciardelli C, Quinn DI, Raymond WA, McCaul K, et al. (1999). Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res. 59: 2324-2328. PMid:10344737   Ricciardelli C, Sakko AJ, Stahl J, Tilley WD, et al. (2009). Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. Prostate 69: 761-769. http://dx.doi.org/10.1002/pros.20926 PMid:19189303   Sakko AJ, Butler MS, Byers S, Reinboth BJ, et al. (2008). Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. Cancer Epidemiol. Biomark. Prev. 17: 2488-2497. http://dx.doi.org/10.1158/1055-9965.EPI-08-0204 PMid:18768520   Suwiwat S, Ricciardelli C, Tammi R, Tammi M, et al. (2004). Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin. Cancer Res. 10: 2491-2498. http://dx.doi.org/10.1158/1078-0432.CCR-03-0146 PMid:15073129   Teng YH, Tan PH, Chia SJ, Zam NA, et al. (2008). Increased expression of non-sulfated chondroitin correlates with adverse clinicopathological parameters in prostate cancer. Mod. Pathol. 21: 893-901. http://dx.doi.org/10.1038/modpathol.2008.70 PMid:18487997   Thiele H, Sakano M, Kitagawa H, Sugahara K, et al. (2004). Loss of chondroitin 6-O-sulfotransferase-1 function results in severe human chondrodysplasia with progressive spinal involvement. Proc. Natl. Acad. Sci. U. S. A. 101: 10155-10160. http://dx.doi.org/10.1073/pnas.0400334101 PMid:15215498 PMCid:454181   Uebelhart D (2008). Clinical review of chondroitin sulfate in osteoarthritis. Osteoarthritis Cartilage 16 (Suppl 3): S19-S21. http://dx.doi.org/10.1016/j.joca.2008.06.006 PMid:18674931   Vijayagopal P, Figueroa JE and Levine EA (1998). Altered composition and increased endothelial cell proliferative activity of proteoglycans isolated from breast carcinoma. J. Surg. Oncol. 68: 250-254. http://dx.doi.org/10.1002/(SICI)1096-9098(199808)68:4<250::AID-JSO9>3.0.CO;2-3   Viloria-Petit AM and Wrana JL (2010). The TGFbeta-Par6 polarity pathway: linking the Par complex to EMT and breast cancer progression. Cell Cycle 9: 623-624. http://dx.doi.org/10.4161/cc.9.4.10779 PMid:20107326   Viloria-Petit AM, David L, Jia JY, Erdemir T, et al. (2009). A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 106: 14028-14033. http://dx.doi.org/10.1073/pnas.0906796106 PMid:19667198 PMCid:2729014   Wandel S, Juni P, Tendal B, Nuesch E, et al. (2010). Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 341: c4675. http://dx.doi.org/10.1136/bmj.c4675 PMid:20847017 PMCid:2941572   Wegrowski Y and Maquart FX (2004). Involvement of stromal proteoglycans in tumour progression. Crit. Rev. Oncol. Hematol. 49: 259-268. http://dx.doi.org/10.1016/j.critrevonc.2003.10.005 PMid:15036265